Table 1.

Percentage of ARGs co-occurring with MGEs before, during, and after antibiotic exposure

Day	Phage integrases	Transposon	Transposase	RteC	Resolvase	Total*
0	1.78 ± 0.69	0.00 ± 0.00	1.93 ± 0.53	0.20 ± 0.28	0.28 ± 0.39	4.19 ± 0.04
1	0.96 ± 0.47	0.00 ± 0.00	3.52 ± 1.00	0.00 ± 0.00	0.18 ± 0.26	4.66 ± 1.72
4	1.36 ± 0.33	0.63 ± 0.45	4.40 ± 0.83	0.19 ± 0.26	0.34 ± 0.47	6.91 ± 1.03
7	2.21 ± 0.84	1.53 ± 0.12	6.09 ± 0.31	0.00 ± 0.00	0.95 ± 0.48	10.78 ± 0.57
11	2.61 ± 2.61	0.00 ± 0.00	3.05 ± 3.05	0.00 ± 0.00	0.29 ± 0.29	5.95 ± 5.95
13	2.72 ± 1.63	0.00 ± 0.00	2.84 ± 0.83	0.41 ± 0.29	0.00 ± 0.00	5.96 ± 2.26
18	1.42 ± 0.56	0.00 ± 0.00	2.32 ± 0.76	0.00 ± 0.00	0.16 ± 0.23	3.91 ± 0.70
26	0.80 ± 0.57	0.00 ± 0.00	2.25 ± 2.09	0.19 ± 0.26	0.62 ± 0.47	3.87 ± 2.30
34	1.12 ± 1.59	0.00 ± 0.00	2.94 ± 2.52	0.00 ± 0.00	0.00 ± 0.00	4.07 ± 1.50
Control	0.93 ± 1.31	0.00 ± 0.00	0.82 ± 1.16	0.27 ± 0.38	0.40 ± 0.56	2.41 ± 1.29

Days under antibiotic treatment are presented in italics. ± indicates the S.D. Control was sampled at day 34

*Total includes ARGs co-occurring with more than one MGE